https://doi.org/10.55788/a55316ac
“Currently, TNM staging for penile squamous cell cancer distinguishes between ‘clinical N3’, with fixed inguinal lymph node metastasis or pelvic lymphadenopathy, and ‘pathologic N3’, with pelvic lymph node metastasis and/or extra-nodal extension in any lymph node,” outlined Dr James Churchill (St George Hospital, Australia). The current study evaluated whether N3 staging can be further stratified based on pelvic lymphadenopathy and extra-nodal extension, to allow more accurate prognostication for patients and guide treatment decisions based on logical stage groupings. It was hypothesised that patients with pelvic lymphadenopathy had a worse prognosis than patients with extra-nodal extension in inguinal lymph node metastasis. In total, 213 patients were analysed retrospectively with OS being the primary outcome.
Patients without pelvic lymphadenopathy and extra-nodal inguinal lymph node extension had an improved OS compared with patients with either pelvic lymphadenopathy (HR 3.67 P<0.001) or inguinal lymph node extra-nodal extension (HR 1.99; P=0.006). Also, a numerical difference was observed between patients with extra-nodal extension (median OS of 25.4 months) and patients with pelvic lymphadenopathy (median OS of 19.6 months; P=0.19). In a corresponding multivariate analysis, patients with pelvic lymphadenopathy displayed 62% increased risk of death, which did not reach statistical significance, compared with patients with inguinal lymph node extra-nodal extension (P=0.072).
- Churchill J, et al. Survival in N3 penile cancer: Does pelvic lymphadenopathy predict a worse prognosis than inguinal extra-nodal extension? Abstract 0691, EAU 2022, 01–04 July.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC Next Article
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma »
« KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC Next Article
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
November 27, 2020
SGLT2 inhibitors appear beneficial in advanced kidney disease, too
May 21, 2019
When to use imaging and imaging-guided therapies
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com